ID   SLR20
AC   CVCL_V606
SY   SLR 20
DR   BioGRID_ORCS_Cell_line; 707
DR   BioSample; SAMN10988419
DR   cancercelllines; CVCL_V606
DR   Cell_Model_Passport; SIDM01341
DR   DepMap; ACH-000127
DR   GEO; GSM374467
DR   PharmacoDB; SLR20_1421_2019
DR   Progenetix; CVCL_V606
DR   Wikidata; Q54954870
RX   PubMed=12907621;
RX   PubMed=19470766;
RX   PubMed=19690146;
RX   PubMed=25984343;
RX   PubMed=28489074;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Problematic cell line: Contaminated. Shown to be a T24 derivative (ICLAC). Originally thought to originate from a clear cell renal cell carcinoma.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00573.
CC   Population: Caucasian; Swedish.
CC   Doubling time: 24 hours (PubMed=25984343).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (DepMap=ACH-000127).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (DepMap=ACH-000127).
CC   Omics: Deep exome analysis.
CC   Omics: shRNA library screening.
CC   Genome ancestry: African=0%; Native American=0.52%; East Asian, North=2.35%; East Asian, South=0%; South Asian=0%; European, North=72.79%; European, South=24.34% (PubMed=30894373).
CC   Miscellaneous: STR profile from personal communication of von Teichman A.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 12
ST   D16S539: 9
ST   D21S11: 29
ST   D5S818: 10,12
ST   D7S820: 10,11
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0554 ! T24
SX   Female
AG   82Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 02-05-24; Version: 21
RX   PubMed=12907621;
RA   Tatsumi T., Herrem C.J., Olson W.C., Finke J.H., Bukowski R.M.,
RA   Kinch M.S., Ranieri E., Storkus W.J.;
RT   "Disease stage variation in CD4+ and CD8+ T-cell reactivity to the
RT   receptor tyrosine kinase EphA2 in patients with renal cell
RT   carcinoma.";
RL   Cancer Res. 63:4481-4489(2003).
RX   PubMed=19470766; DOI=10.1158/0008-5472.CAN-09-0146;
RA   Beroukhim R., Brunet J.-P., Di Napoli A., Mertz K.D., Seeley A.,
RA   Pires M.M., Linhart D., Worrell R.A., Moch H., Rubin M.A.,
RA   Sellers W.R., Meyerson M.L., Linehan W.M., Kaelin W.G. Jr.,
RA   Signoretti S.;
RT   "Patterns of gene expression and copy-number alterations in von-Hippel
RT   Lindau disease-associated and sporadic clear cell carcinoma of the
RT   kidney.";
RL   Cancer Res. 69:4674-4681(2009).
RX   PubMed=19690146; DOI=10.1158/0008-5472.CAN-08-4511;
RA   Kawabe M., Mandic M., Taylor J.L., Vasquez C.A., Wesa A.K.,
RA   Neckers L.M., Storkus W.J.;
RT   "Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-
RT   demethoxygeldanamycin enhances EphA2+ tumor cell recognition by
RT   specific CD8+ T cells.";
RL   Cancer Res. 69:6995-7003(2009).
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
RX   PubMed=28489074; DOI=10.1038/ncomms15165;
RA   Sinha R., Winer A.G., Chevinsky M., Jakubowski C., Chen Y.-B., Dong Y.-Y.,
RA   Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C.,
RA   Hsieh J.J.-D., Hakimi A.A.;
RT   "Analysis of renal cancer cell lines from two major resources enables
RT   genomics-guided cell line selection.";
RL   Nat. Commun. 8:15165.1-15165.10(2017).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).